VacZine Analytics  
MarketVIEW: Lyme Borreliosis vaccines

Published: June 2019

Lyme Borreliosis (LB) or Lyme disease is caused by an infection with the bacterial spirochete Borrelia genospecies. The pathogen is transmitted to humans through the bite of infected Ixodes tick species. LB, which is endemic in large areas of Europe and North America, can cause a wide range of disease symptoms which range from a mild treatable rash (erythema migrans, EM) to serious multistage complications of the neurological (neuroborreliosis) and musculoskeletal systems. Aside from increased awareness and testing, experts believe the incidence of LB is increasing partly due to expanding vector populations. There are an estimated 300,000 cases of Lyme disease annually each in the US and EU. The disease is significantly underreported and has high profile chronic implications for many individuals.

GSK Biologicals licensed an OspA-based recombinant vaccine (LYMErix) in 1998 which was later withdrawn due to several reasons. Both Baxter Vaccines and Sanofi Pasteur were developing OspA-based approaches, but development was halted. Valneva appear to have the only human Lyme Disease vaccine in development (VLA15) which is advancing through Phase II studies. There are many drivers to vaccine development but also controversies and challenges.

This MarketVIEW product is composed of a comprehensive Executive summary presentation (197 slides, .pdf) + MS Excel-based model which forecasts the potential commercial value of a putative Lyme Borreliosis vaccines across 27 major Western markets to 2040. Both adult and pediatric, as well as risk-persons,are considered with 3 pricing scenarios (LO, BASE and HI). A detailed review of disease background and epidemiology is included along with current treatment, unmet needs and rationale for vaccine approach with a review of the latest key working group viewpoints. Target Product Profiles (TPP) are defined based on recent R&D understanding, along with commercial model assumptions. This analysis is ideally suited to any organisation wishing to understand and justify new investment into this highly important opportunity.


THIS PRODUCT IS A SUMMARY PRESENTATION (.pdf, 197 slides) + 1 MODEL (.xls, >75 worksheets)

To order please contact your region account manager, buy "on-line" or order direct at: orders@vaczine-analytics.com

CAT No: CONTENTS: PURCHASE:
VAMV024 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. On-line prices may include discounts and are converted from list price in US dollars (subject to currency fluctuations). Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?






© 2017 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains